Arrowstreet Capital Limited Partnership Raises Stock Holdings in Bausch + Lomb Co. (NYSE:BLCO)

Arrowstreet Capital Limited Partnership raised its position in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 51.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,218,431 shares of the company's stock after acquiring an additional 414,138 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.35% of Bausch + Lomb worth $21,996,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. boosted its stake in shares of Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after buying an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Bausch + Lomb during the fourth quarter worth $72,000. Commonwealth Equity Services LLC purchased a new position in Bausch + Lomb in the fourth quarter worth $181,000. Orion Portfolio Solutions LLC bought a new position in Bausch + Lomb in the 4th quarter valued at $225,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bausch + Lomb during the 3rd quarter valued at $289,000. Institutional investors own 11.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BLCO. Wells Fargo & Company restated an "equal weight" rating and set a $15.00 price target (down previously from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Bank of America reduced their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research report on Thursday, February 20th. Stifel Nicolaus lowered their price target on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a report on Thursday, April 3rd. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a report on Thursday, February 20th. Finally, Royal Bank of Canada lowered their target price on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $18.82.

Remove Ads

Bausch + Lomb Price Performance

Shares of BLCO traded down $0.95 during midday trading on Tuesday, hitting $10.93. 784,396 shares of the company traded hands, compared to its average volume of 619,064. Bausch + Lomb Co. has a one year low of $10.88 and a one year high of $21.69. The firm has a market cap of $3.85 billion, a P/E ratio of -12.01, a PEG ratio of 0.85 and a beta of 0.54. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. The stock has a 50-day moving average of $15.50 and a 200-day moving average of $17.80.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the prior year, the firm posted $0.24 EPS. Bausch + Lomb's revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts predict that Bausch + Lomb Co. will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.